Coya Therapeutics (COYA) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Coya Therapeutics (COYA) over the past year, losing 14.7% versus a loss of 20.9%. Coya Therapeutics is the larger company by market cap ($116.4 million vs $113.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | UNCY |
|---|---|---|
| Share price | $4.96 | $4.13 |
| Market cap | $116.35M | $113.00M |
| 1-day change | -0.60% | +1.35% |
| YTD return | -13.97% | -29.46% |
| 1-year return | -20.92% | -14.68% |
| 5-year return | — | -85.06% |
| Forward P/E | — | 2.45 |
| EPS (TTM) | $-1.07 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $8.74 |
| 52-week low | $3.71 | $3.93 |
| Distance from 52-week high | -36.00% | -52.80% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +206.65% | +588.48% |
| Average volume | 158.05K | 839.29K |
| Shares outstanding | 23.46M | 27.39M |
| Employees | 8 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
COYA vs UNCY FAQ
Which is bigger, Coya Therapeutics or Unicycive Therapeutics?
Coya Therapeutics (COYA) is larger, with a market capitalization of $116.35M compared with $113.00M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, COYA or UNCY?
UNCY returned -14.68% over the past 12 months, compared with -20.92% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.